NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 928.8 DKK | -0.92% |
|
+2.82% | +33.05% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
937.4
DKK
Average target price
909.2
DKK
Spread / Average Target
-3.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.05% | 603B | |
| +38.94% | 728B | |
| -5.45% | 360B | |
| +18.78% | 332B | |
| +1.39% | 279B | |
| +16.00% | 244B | |
| +8.09% | 207B | |
| -5.77% | 205B | |
| +6.43% | 164B | |
| -0.27% | 122B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Financial Stocks Burden European Equities Again Friday Trading
